Tumor, Solid Clinical Trial
Official title:
Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
This study will examine whether patients with relapsed/refractory solid tumors harboring evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will exhibit improvement in disease progression-free survival with dual Tremelimumab and Durvalumab treatment.
This study is phase II basket trial to evaluate the benefit of immunotherapy (Durvalumab and Tremelimumab combination) in treatment of relapse/refractory solid tumor patients whose tumors express a high tumor mutational burden (TMB high >20 mutations/MB) or moderate tumor mutational burden (10-20 mutations/MB) as based on next generation sequencing (NGS). The primary endpoint of the study is the TTP (time-to-progression) ratio or growth modulation index (GMI) which is defined for individual patients as the ratio of their TTP on the current therapy to their TTP on the most recent previous therapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05637034 -
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
|
N/A | |
| Terminated |
NCT04095091 -
Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)
|
||
| Recruiting |
NCT05378425 -
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
|
Phase 1 | |
| Not yet recruiting |
NCT04723810 -
TumorGlow Intraoperative Molecular Imaging (IMI)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06116032 -
Immune Profiling for Cancer Immunotherapy Response
|
||
| Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
| Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04750772 -
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
|
N/A | |
| Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
| Terminated |
NCT01358331 -
A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)
|
Phase 1 | |
| Recruiting |
NCT06175221 -
Autologous TLPO Vaccine Basket
|
Phase 2 | |
| Recruiting |
NCT05661461 -
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
|
Phase 1 | |
| Active, not recruiting |
NCT04196530 -
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
|
Phase 1 | |
| Not yet recruiting |
NCT03731390 -
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT03491631 -
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06193902 -
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04528836 -
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05221320 -
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
|
Phase 2 |